Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced/Metastatic Solid Tumors: early-phase trial registry
4 of 5 indexed Advanced/Metastatic Solid Tumors trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 4 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Advanced/Metastatic Solid Tumors: 5 US clinical trials tracked, 4 recruiting.
Advanced/Metastatic Solid Tumors is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Adagene, running 1 of these trials.
Enrollment posture brief
Registry condition advancedmetastatic-solid-tumors
OPEN 4 | RECR 80% | LATE 0 | EARLY 5 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Leukemia of Ambiguous Lineage (80% recruiting · 10 trials)
Advanced/Metastatic Solid Tumors lists 4 open slots (80% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced/Metastatic Solid Tumors on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced/Metastatic Solid Tumors is recruiting above its size-band peers.
4 of 5 indexed trials (80%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Advanced/Metastatic Solid Tumors research.
Adagene accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Typical Advanced/Metastatic Solid Tumors enrolment sits around 233 participants.
Median target enrolment is 233 among the 5 trials that report a genuine target (sentinel values excluded). 1 of those (20%) plan for fewer than 100 participants.
-
Advanced/Metastatic Solid Tumors research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Merus B.V.
NCT03526835
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Pfizer
NCT07090499
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
DualityBio
NCT07141706
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Adagene
NCT05405595
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
Merck Sharp & Dohme
NCT05514444
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced/Metastatic Solid Tumors records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced/Metastatic Solid Tumors trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced/Metastatic Solid Tumors page
5 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Advanced/Metastatic Solid Tumors trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Adagene sponsors the most Advanced/Metastatic Solid Tumors trials on record, review their full trial history before evaluating a specific study. See Adagene's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced/Metastatic Solid Tumors condition card totals 5 registered trials; most-linked intervention 89Zr-MK-4464; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.